Nykode Therapeutics AS

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

57

Website

nykode.com

Country

🇳🇴 Norway

Exchange

Oslo

Founded 2006Oslo, Norway

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases.

Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial

VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Founded in 2006, Nykode Therapeutics is headquartered in Oslo, Norway.

Key Stats

52-Week Range

kr 1.44kr 4.10

Beta0.83

Trailing P/EN/A

Forward P/E-23.10

Trailing EPS-0.48

Avg Volume

Earnings & Analyst

Next Earnings2026-08-26

EPS EstimateN/A

Target Mean Pricekr 5.00

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.